Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy DOI Creative Commons
Giuseppe Longobardi, Thomas L. Moore, Claudia Conte

et al.

Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, Journal Year: 2024, Volume and Issue: 16(5)

Published: Sept. 1, 2024

Abstract Polymeric nanoparticles (NPs), specifically those comprised of biodegradable and biocompatible polyesters, have been heralded as a game‐changing drug delivery platform. In fact, poly(α‐hydroxy acids) such polylactide (PLA), poly(lactide‐ co ‐glycolide) (PLGA), poly(ε‐caprolactone) (PCL) heavily researched in the past three decades material basis polymeric NPs for applications. As materials, these polymers found success resorbable sutures, implants, even monolithic, platforms sustained release therapeutics (e.g., proteins small molecules) diagnostics. Few fields gained more attention through than cancer therapy. However, clinical translational nanomedicines treating solid tumors has not congruent with fervor or funding this particular field research. Here, we attempt to provide comprehensive snapshot polyester context chemotherapeutic delivery. This includes preliminary exploration nanomedicine research space. We examine various processes producing NPs, including methods surface‐functionalization, related challenges. After detailed overview multiple factors involved tumors, crosstalk between particle design interactions biological systems is discussed. Finally, report state‐of‐the‐art approaches toward effective aiming at identifying new areas re‐evaluating reasons why some avenues underdelivered. hope our effort will contribute better understanding gap fill delineate future work needed bring polyester‐based closer application. article categorized under: Therapeutic Approaches Drug Discovery > Nanomedicine Oncologic Disease Nanotechnology Biology Nanoscale Systems Emerging Technologies

Language: Английский

Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging DOI Creative Commons
Ibrahim Alradwan,

Nojoud AL Fayez,

Mohammad N. Alomary

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(8), P. 1037 - 1037

Published: Aug. 3, 2024

Cardiovascular diseases (CVDs) are classed as of aging, which associated with an increased prevalence atherosclerotic lesion formation caused by such and is considered one the leading causes death globally, representing a severe health crisis affecting heart blood vessels. Atherosclerosis described chronic condition that can lead to myocardial infarction, ischemic cardiomyopathy, stroke, peripheral arterial disease date, most pharmacological therapies mainly aim control risk factors in patients cardiovascular disease. Advances transformative imaging diagnostics agents could shape clinical applications approaches, including nanomedicine, biomaterials, immunotherapy, cell therapy, gene emerging likely significantly impact CVD management coming decade. This review summarizes current anti-atherosclerotic therapies’ major milestones, strengths, limitations. It provides overview recent discoveries technologies immune therapeutics revolutionize practice steering it toward precision medicine. CVD-related trials promising pre-clinical strategies would discussed. Here, we these advances, highlighting key opportunities rapidly field

Language: Английский

Citations

9
Small molecule modulation of protein corona for deep plasma proteome profiling DOI Creative Commons
Ali Akbar Ashkarran, Hassan Gharibi,

Seyed Amirhossein Sadeghi

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: Nov. 7, 2024

The protein corona formed on nanoparticles (NPs) has potential as a valuable diagnostic tool for improving plasma proteome coverage. Here, we show that spiking small molecules, including metabolites, lipids, vitamins, and nutrients into can induce diverse patterns otherwise identical NPs, significantly enhancing the depth of profiling. coronas polystyrene NPs when exposed to treated with an array molecules allows detection 1793 proteins marking 8.25-fold increase in number quantified compared alone (218 proteins) 2.63-fold relative untreated (681 proteins). Furthermore, discovered adding 1000 µg/ml phosphatidylcholine could singularly enable 897 proteins. At this specific concentration, selectively depletes four most abundant proteins, albumin, thus reducing dynamic range enabling lower abundance. Employing optimized data-independent acquisition approach, inclusion leads 1436 single sample. Our molecular dynamics results reveal interacts albumin via hydrophobic interactions, H-bonds, water bridges. addition also enables 337 additional proteoforms using top-down proteomics approach. Given critical role biomarker discovery disease monitoring, anticipate widespread adoption methodology identification clinical translation biomarkers.

Language: Английский

Citations

9
Unveiling the challenges of engineered protein corona from the proteins’ perspective DOI Creative Commons

Cintia Marques,

Gerrit Borchard, Olivier Jordan

et al.

International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 654, P. 123987 - 123987

Published: March 11, 2024

It is well known that protein corona affects the "biological identity" of nanoparticles (NPs), which has been seen as both a challenge and an opportunity. Approaches have moved from avoiding adsorption to trying direct it, taking advantage formation favorably modify pharmacokinetic parameters NPs. Although promising, results obtained with engineered NPs still need be completely understood. While much effort put into understanding how surface nanomaterials absorption, less about proteins can affect due their specific physicochemical properties. This review addresses this knowledge gap, examining key factors influencing formation, highlighting current challenges in studying protein–protein interactions, discussing future perspectives field.

Language: Английский

Citations

7
The nanoparticle-Protein Corona untold history (1907–2007) DOI
Eudald Casals, Michele Vitali, Víctor Puntes

et al.

Nano Today, Journal Year: 2024, Volume and Issue: 58, P. 102435 - 102435

Published: Aug. 5, 2024

Language: Английский

Citations

7
Protein Coronation-Induced Cancer Staging-Dependent Multilevel Cytotoxicity: An All-Humanized Study in Blood Vessel Organoids DOI
Chan Wang,

Yingyi Quan,

Jiang Jiang

et al.

ACS Nano, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

The protein corona effect refers to the phenomenon wherein nanomaterials in bloodstream are coated by serum proteins, yet how coronated interact with blood vessels and its toxicity implications remain poorly understood. In this study, we investigated corona-related vessel using an all-humanized assay integrating organoids patient-derived serum. Initially, screened various discern parameters including size, morphology, hydrophobicity, surface charge, chirality-dependent difference influence their uptake organoids. For showing substantial differences uptake, was analyzed label-free mass spectra. Our findings revealed involvement of cancer staging-related cytoskeleton components mediating preferential cells, endothelial mural cells. Additionally, a transcriptome study conducted elucidate nanomaterials. We confirmed that provoke remodeling at both transcriptional translational levels, impacting pathways such as PI3K-Akt/Hippo/Wnt, membraneless organelle integrity, respectively. further demonstrated potential can be harnessed synergize antiangiogenesis therapeutics improve outcomes. anticipate will provide guidance for safe use nanomedicine future.

Language: Английский

Citations

1
Molecular dynamics in pharmaceutical nanotechnology: simulating interactions and advancing applications DOI
Anand B. Mundada, Prashanta Chandra Pradhan, Rajapandi Raju

et al.

Journal of Biomaterials Science Polymer Edition, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 27

Published: Jan. 9, 2025

Molecular Dynamics (MD) simulations are now widely utilized in pharmaceutical nanotechnology to gain deeper understanding of nanoscale processes imperative drug design. This review has also detailed how MD simulation can be employed the study drug-nanocarrier interactions, controlling release chemical compounds from delivery systems and increasing solubility bioavailability nanocarriers. Furthermore, contributes examining systems, measuring toxic effects, determining biocompatibility nanomedical systems. With incorporation artificial intelligence use hybrid gone a step ahead model other niches biology that make tremendous opening develop highly selective nanomedications. Nevertheless, with well-known issues such as computational constraints discrepancy between silico experiment results, remains work progress, considerable promise for replacing or supplementing existing approaches development precision medicine nanomedicine, continued progression healthcare hopeful.

Language: Английский

Citations

1
Splenic response to protein corona of nanoparticles in vivo DOI
Can Chen, Yueping Li, Dandan Zhou

et al.

Nano Today, Journal Year: 2025, Volume and Issue: 62, P. 102676 - 102676

Published: March 1, 2025

Language: Английский

Citations

1
Ai-driven prediction of cardio-oncology biomarkers through protein corona analysis DOI
Avirup Guha,

Seyed Amirhossein Sadeghi,

Harikrishnan Hyma Kunhiraman

et al.

Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: 509, P. 161134 - 161134

Published: March 1, 2025

Language: Английский

Citations

1
Splenic B cell-targeting lipid nanoparticles for safe and effective mRNA vaccine delivery DOI Creative Commons
Yuichi Suzuki,

Mai Yakuwa,

Mina Sato

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: unknown, P. 113687 - 113687

Published: April 1, 2025

Language: Английский

Citations

1
In Vitro and In Vivo Evaluation of the Pathology and Safety Aspects of Three- and Four-Way Junction RNA Nanoparticles DOI

Kai Jin,

You-Cheng Liao, Tzu‐Chun Cheng

et al.

Molecular Pharmaceutics, Journal Year: 2024, Volume and Issue: 21(2), P. 718 - 728

Published: Jan. 12, 2024

RNA therapeutics has advanced into the third milestone in pharmaceutical drug development, following chemical and protein therapeutics. itself can serve as therapeutics, carriers, regulators, or substrates development. Due to RNA's motile, dynamic, deformable properties, nanoparticles have demonstrated spontaneous targeting accumulation cancer vasculature fast excretion through kidney glomerulus urine prevent possible interactions with healthy organs. Furthermore, negatively charged phosphate backbone of results general repulsion from lipid cell membranes for further avoidance vital Thus, spontaneously enrich tumor efficiently enter cells via specific targeting, while those not entering tissue will clear body quickly. These favorable parameters led expectation that low little toxicity. been well characterized their anticancer efficacy; however, detail on nanoparticle pathology safety is known. Here, we report

Language: Английский

Citations

6